$117.86
2.26% yesterday
Nasdaq, Sep 11, 10:04 pm CET
ISIN
US3755581036
Symbol
GILD

Gilead Sciences Stock price

$117.86
-2.61 2.17% 1M
+3.43 3.00% 6M
+25.49 27.60% YTD
+36.92 45.61% 1Y
+49.85 73.30% 3Y
+52.28 79.72% 5Y
+8.23 7.51% 10Y
+106.52 939.10% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
+2.61 2.26%
ISIN
US3755581036
Symbol
GILD
Industry

Key metrics

Basic
Market capitalization
$146.2b
Enterprise Value
$166.0b
Net debt
$19.7b
Cash
$5.2b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
23.5 | 14.3
P/S
5.1 | 5.0
EV/Sales
5.8 | 5.7
EV/FCF
18.2
P/B
7.4
Dividends
DPS
$3.08
Yield 1Y | 5Y
2.6% | 4.0%
Growth 1Y | 5Y
2.7% | 4.1%
Payout 1Y | 3Y
810.5% | 105.6%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$28.9b | $29.3b
EBITDA
$15.2b | $14.6b
EBIT
$11.0b | $13.5b
Net Income
$6.3b | $10.3b
Free Cash Flow
$9.1b
Growth (TTM | estimate)
Revenue
3.8% | 2.0%
EBITDA
15.3% | 7.3%
EBIT
5.9% | 24.4%
Net Income
499.3% | 2,037.3%
Free Cash Flow
32.5%
Margin (TTM | estimate)
Gross
78.5%
EBITDA
52.5% | 49.7%
EBIT
38.1%
Net
21.9% | 35.0%
Free Cash Flow
31.7%
Financial Health
Equity Ratio
32.8%
Return on Equity
2.5%
ROCE
24.7%
ROIC
20.8%
Debt/Equity
1.3
More
EPS
$5.0
FCF per Share
$7.4
Short interest
1.5%
Employees
18k
Rev per Employee
$1.6m
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

28x Buy
78%
8x Hold
22%

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

Buy
78%
Hold
22%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
28,863 28,863
4% 4%
100%
- Direct Costs 6,196 6,196
1% 1%
21%
22,667 22,667
5% 5%
79%
- Selling and Administrative Expenses 5,846 5,846
5% 5%
20%
- Research and Development Expense 5,818 5,818
4% 4%
20%
15,158 15,158
15% 15%
53%
- Depreciation and Amortization 4,154 4,154
51% 51%
14%
EBIT (Operating Income) EBIT 11,004 11,004
6% 6%
38%
Net Profit 6,311 6,311
499% 499%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Neutral
Seeking Alpha
one day ago
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Participants Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Presentation Brian Skorney Senior Research Analyst Good afternoon, everyone.
Neutral
Seeking Alpha
2 days ago
Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Well, thanks, everyone, for joining us.
Neutral
Business Wire
7 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coo...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today